WindMIL Therapeutics
Business Services · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1812 Ashland Ave Ste 100, Baltimore, Mar...Website
www.windmiltherapeutics.comRevenue
$6.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About WindMIL Therapeutics
WindMIL Therapeutics is a clinical-stage biotechnology company focused on developing a novel class of cell-based immuno-oncology therapies. The company specializes in utilizing marrow-infiltrating lymphocytes (MILs) extracted from cancer patients' bone marrow, which are then activated and expanded to create effective treatments. WindMIL's technology offers broad antigen specificity, a rich supply of memory T cells, low toxicity, and eliminates the need for genetic manipulation, making it a promising option for cancer therapy. The company aims to provide innovative solutions for cancer patients, leveraging its proprietary processes and expertise in immunotherapy.Explore more
WindMIL Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is WindMIL Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
WindMIL Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when WindMIL Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once WindMIL Therapeutics has new funding data
Check out if WindMIL Therapeutics is spiking on competitors!
Earning: See what the market has to say on WindMIL Therapeutics recently announced quarterly report
Click to see if WindMIL Therapeutics had a recent Job posting/layoffs
Check if WindMIL Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at WindMIL Therapeutics
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to WindMIL Therapeutics
Compare insights from companies similar to WindMIL Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
WindMIL Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
WindMIL Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about WindMIL Therapeutics.
WindMIL Therapeutics financials insights
Gather financial insights about WindMIL Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$10M
2018
Series B
$32.5M
2021
Other Financing Round
$2.3M
WindMIL Therapeutics Tech Stack
A closer look at the technologies used by WindMIL Therapeutics
Most Recent Scoops
Left Company
Executive Move
Funding
Left Company
Executive Move
Karen LaRochelle, Senior VP, Corporate & Business Development, has left the organization and now serves as Chief Business Officer at Artax Biopharma , Inc..
New Hire
Executive Move
Patrick Fabbio has been named Chief Financial Officer.
Executive Moves, New Hire, Personnel Moves
Lateral Move
Executive Move
Executive Moves, Lateral Move
WindMIL Therapeutics News & Media
Cell therapy developer WindMIL Therapeutics raises $2.3M
The company's lead product candidate is in mid-stage clinical testing as a potential treatment for patients with non-small cell lung cancer.WindMIL Therapeutics Presents New Marrow-Infiltrating Lymphocytes (MILs®) Data Demonstrating Broad Therapeutic Promise for Solid Tumor Cancers
PHILADELPHIA and BALTIMORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer immunotherapy, today presented new data demonstrating the therapeutic promise for MILs as a potential cancer immunotherapy for a wide range of solid tumor indications at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting.WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs®) Data Selected for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
PHILADELPHIA and BALTIMORE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer immunotherapy, today announced that data regarding MILs® as a potential cancer immunotherapy for hematological and solid tumors has been selected for a poster presentation at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting which will take place virtually November 9 – 14, 2020.WindMIL Therapeutics and Stephenson Cancer Center Announce Collaboration to Collect Bone Marrow from Patients with Renal and Urothelial Carcinomas to Develop Marrow Infiltrating Lymphocytes (MILs®)
PHILADELPHIA, BALTIMORE and OKLAHOMA CITY, Oct. 13, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics (WindMIL) and Stephenson Cancer Center today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with renal (RCC) and urothelial carcinomas (UC). The study will evaluate generating marrow infiltrating lymphocytes (MILs®) for these patients through WindMIL’s proprietary cellular activation and expansion process. The
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding WindMIL Therapeutics
Sign Up For FreeTo access detailed company insights
WindMIL Therapeutics is a clinical-stage biotechnology company focused on developing a novel class of cell-based immuno-oncology therapies. The company specializes in utilizing marrow-infiltrating lymphocytes (MILs) extracted from cancer patients' bone marrow, which are then activated and expanded to create effective treatments. WindMIL's technolog... Read More
